Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10570214
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
granted -
US 10568863
CPC distribution chromatography of cannabinoids
granted -
US 10570151
Biologically active molecules, conjugates thereof, and therapeutic uses
granted -
US 10570120
Neprilysin inhibitors
granted -
US 10570092
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 10568963
Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed by post-loading photosensitizer and fluorophore to polyacrylamide nanoparticles
granted -
US 10568880
Glucocorticoid receptor modulators to treat cervical cancer
granted -
US 10568844
RNAi molecule delivery platform based on single-siRNA and shRNA nanocapsules
granted -
US 10568828
Peptide having hair growth-promoting activity and use thereof
granted -
US 10568855
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 10568888
Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
granted -
US 10568898
Lipophilic nanoparticles for drug delivery
granted -
US 10568891
Vaginal inserted estradiol pharmaceutical compositions and methods
granted -
US 10568901
Micro-RNA for the treatment of malignant solid tumors and metastasis
granted -
US 10568831
Method to enhance swallowing safety and appeal of beverages for treating dysphagia based on rheological and sensory parameters
granted -
US 10568877
Preparation and anti-HSV-1 application of quinolinone derivatives
granted -
US 10568873
Safranal-sorafenib combination therapy for liver cancer
granted -
US 10568913
Method for generating mature β-like cells
granted -
US 10568943
Factor IX polypeptides and methods of use thereof
granted -
US 10570115
Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
granted -
US 10570126
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 10570172
Self-assembling amphiphilic peptides
granted -
US 10568977
Antibodies that bind activatable antibodies and methods of use thereof
granted -
US 10569067
Controlled release nanoparticulate matter delivery system
granted -
US 10570140
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 10570124
Deoxycytidine kinase binding compounds
granted -
US 10570169
Conjugated antisense compounds and their use
granted -
US 10570186
Chimeric antigen receptors (CAR) to selectively target protein complexes
granted -
US 10570391
RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
granted -
US 10570183
Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
granted -
US 10570418
Methods and compositions for RNA-directed target DNA modification
granted -
US 10568871
Triazolone compounds and uses thereof
granted -
US 10570128
Agonists of the apelin receptor and methods of use thereof
granted -
US 10570185
Method to detect autoantibody reactivity for deamidated insulin autoantigen in diabetes
granted -
US 10570401
Compositions and method for destabilizing, altering, and dispersing biofilms
granted -
US 10570453
Method of predicting a predisposition to QT prolongation
granted -
US 10570382
Transposase polypeptides and uses thereof
granted -
US 10568919
Composition for lowering blood lipids and use thereof
granted -
US 10570153
Benzodiazepine derivatives as RSV inhibitors
granted -
US 10568956
Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
granted -
US 10570091
Method for producing pyrrole compound
granted -
US 10570393
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
granted -
US 10570419
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10570452
Method of predicting a predisposition to QT prolongation
granted -
US 10576079
Multi-drug therapies for tuberculosis treatment
granted -
US 10575521
Antimicrobial, antibacterial and spore germination inhibiting activity from an avocado extract enriched in bioactive compounds
granted -
US 10576096
Tumor-selective combination therapy
granted -
US 10577631
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.